Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02719691 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT02719691 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 47 participants.
The verdict
NCT02719691, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a phase Ib study designed to evaluate the safety and toxicity of the combination of Alisertib and MLN0128 in patients with advanced solid tumors with an expansion cohort in patients with previously treated metastatic TNBC.
Interventions
- DRUG Alisertib
- DRUG MLN0128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2016-05-13 |
| Est. Completion | 2020-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02719691
The ClinicalTrials.gov registry entry for NCT02719691 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alisertib is the first listed.
NCT02719691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02719691 about?
NCT02719691 is a clinical study titled "Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer". This is a phase Ib study designed to evaluate the safety and toxicity of the combination of Alisertib and MLN0128 in patients with advanced solid tumors with an expansion cohort in patients with previously treated metastatic TNBC.
What is the current status of trial NCT02719691?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2016-05-13. Estimated completion is 2020-03-18.
What interventions are being tested in trial NCT02719691?
The interventions under investigation include: Alisertib (DRUG), MLN0128 (DRUG).
Who is sponsoring clinical trial NCT02719691?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.